(Q44818567)

English

Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International

scientific article published in April 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

author name string

Sambrook PN

1

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Geusens P

2

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Ribot C

3

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Solimano JA

4

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Ferrer-Barriendos J

5

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Gaines K

6

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Verbruggen N

7

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Melton ME

8

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

language of work or name

0 references

publication date

1 April 2004

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Journal of Internal Medicine

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

255

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

503-511

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Antifracture efficacy of antiresorptive agents are related to changes in bone density.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01317.X

21 January 2018

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01317.X

21 January 2018

Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01317.X

21 January 2018

A comprehensive review of treatments for postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01317.X

21 January 2018

Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01317.X

21 January 2018

Colles' fracture of the wrist as an indicator of underlying osteoporosis in postmenopausal women: a prospective study of bone mineral density and bone turnover rate

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01317.X

21 January 2018

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01317.X

21 January 2018

Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01317.X

21 January 2018

Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01317.X

21 January 2018

Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01317.X

21 January 2018

Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01317.X

21 January 2018

Uncertain future of trials in osteoporosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01317.X

21 January 2018

Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01317.X

21 January 2018

Effects of raloxifene on bone density, biomarkers, and histomorphometric and biomechanical measures in ovariectomized cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01317.X

21 January 2018

Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2004.01317.X

21 January 2018

Identifiers

10.1111/J.1365-2796.2004.01317.X

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44818567&oldid=2047822929"